Biomarker hub
BRAF V600E
Trials and papers mentioning BRAF V600E.
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
ACTIVE_NOT_RECRUITING · Phase not listed
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
ACTIVE_NOT_RECRUITING · Phase not listed
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
RECRUITING · Phase not listed
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RECRUITING · Phase not listed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
RECRUITING · Phase not listed
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase not listed
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
RECRUITING · Phase not listed
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
TERMINATED · Phase not listed
Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy
TERMINATED · Phase not listed
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
AVAILABLE · Phase not listed
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
RECRUITING · Phase not listed
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
ACTIVE_NOT_RECRUITING · Phase not listed
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
RECRUITING · Phase not listed
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
RECRUITING · Phase not listed
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase not listed
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
ACTIVE_NOT_RECRUITING · Phase not listed
Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples
RECRUITING · Phase not listed
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
RECRUITING · Phase not listed
A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
COMPLETED · Phase not listed
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
RECRUITING · Phase not listed
Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatment.
iScience · 2/20/2026
BRAF/MEK Inhibition Induces Cell State Transitions Boosting Immune CheckpointSensitivity in BRAFV600E-mutant Glioma
cancer biology · 4/1/2025
Ethnicity-specific molecular alterations in MAPK and JAK/STAT pathways in early-onset colorectal cancer
genetic and genomic medicine · 2/24/2025